Pulike Biological Engineering Balance Sheet Health
Financial Health criteria checks 6/6
Pulike Biological Engineering has a total shareholder equity of CN¥2.6B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥3.1B and CN¥451.6M respectively. Pulike Biological Engineering's EBIT is CN¥72.9M making its interest coverage ratio -12.2. It has cash and short-term investments of CN¥566.5M.
Key information
0%
Debt to equity ratio
CN¥0
Debt
| Interest coverage ratio | -12.2x |
| Cash | CN¥566.46m |
| Equity | CN¥2.64b |
| Total liabilities | CN¥451.59m |
| Total assets | CN¥3.09b |
Recent financial health updates
Recent updates
Investors Still Waiting For A Pull Back In Pulike Biological Engineering, Inc. (SHSE:603566)
Jan 03
Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture
Sep 04Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump
May 21Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024
Apr 28Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E
Mar 21Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly
Feb 28Financial Position Analysis
Short Term Liabilities: 603566's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥411.3M).
Long Term Liabilities: 603566's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥40.3M).
Debt to Equity History and Analysis
Debt Level: 603566 is debt free.
Reducing Debt: 603566 had no debt 5 years ago.
Debt Coverage: 603566 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 603566 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 23:56 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pulike Biological Engineering, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jia Chen | Changjiang Securities Co. LTD. |
| Bo Chen | Chasing Securities |
| Xie Zhiyou | China Galaxy Securities Co., Ltd. |